15264437

Source:http://linkedlifedata.com/resource/pubmed/id/15264437

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists.
Subject	Predicate	Object	Context
pubmed-article:15264437	rdf:type	pubmed:Citation	lld:pubmed
pubmed-article:15264437	lifeskim:mentions	umls-concept:C0039421	lld:lifeskim
pubmed-article:15264437	lifeskim:mentions	umls-concept:C0220825	lld:lifeskim
pubmed-article:15264437	lifeskim:mentions	umls-concept:C1328025	lld:lifeskim
pubmed-article:15264437	pubmed:issue	3	lld:pubmed
pubmed-article:15264437	pubmed:dateCreated	2004-7-21	lld:pubmed
pubmed-article:15264437	pubmed:abstractText	Genentech, Roche and Chugai are developing pertuzumab, a next-generation trastuzumab-like molecule (an anti-HER/neu monoclonal antibody), for the potential treatment of cancer. Pertuzumab is currently undergoing phase II clinical trials.	lld:pubmed
pubmed-article:15264437	pubmed:language	eng	lld:pubmed
pubmed-article:15264437	pubmed:journal	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:15264437	pubmed:citationSubset	IM	lld:pubmed
pubmed-article:15264437	pubmed:chemical	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:15264437	pubmed:chemical	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:15264437	pubmed:chemical	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:15264437	pubmed:chemical	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:15264437	pubmed:status	MEDLINE	lld:pubmed
pubmed-article:15264437	pubmed:month	Jun	lld:pubmed
pubmed-article:15264437	pubmed:issn	1464-8431	lld:pubmed
pubmed-article:15264437	pubmed:author	pubmed-author:SpicerJamesJ	lld:pubmed
pubmed-article:15264437	pubmed:issnType	Print	lld:pubmed
pubmed-article:15264437	pubmed:volume	6	lld:pubmed
pubmed-article:15264437	pubmed:owner	NLM	lld:pubmed
pubmed-article:15264437	pubmed:authorsComplete	Y	lld:pubmed
pubmed-article:15264437	pubmed:pagination	337-43	lld:pubmed
pubmed-article:15264437	pubmed:dateRevised	2011-11-17	lld:pubmed
pubmed-article:15264437	pubmed:meshHeading	pubmed-meshheading:15264437...	lld:pubmed
pubmed-article:15264437	pubmed:meshHeading	pubmed-meshheading:15264437...	lld:pubmed
pubmed-article:15264437	pubmed:meshHeading	pubmed-meshheading:15264437...	lld:pubmed
pubmed-article:15264437	pubmed:meshHeading	pubmed-meshheading:15264437...	lld:pubmed
pubmed-article:15264437	pubmed:meshHeading	pubmed-meshheading:15264437...	lld:pubmed
pubmed-article:15264437	pubmed:meshHeading	pubmed-meshheading:15264437...	lld:pubmed
pubmed-article:15264437	pubmed:meshHeading	pubmed-meshheading:15264437...	lld:pubmed
pubmed-article:15264437	pubmed:meshHeading	pubmed-meshheading:15264437...	lld:pubmed
pubmed-article:15264437	pubmed:meshHeading	pubmed-meshheading:15264437...	lld:pubmed
pubmed-article:15264437	pubmed:meshHeading	pubmed-meshheading:15264437...	lld:pubmed
pubmed-article:15264437	pubmed:meshHeading	pubmed-meshheading:15264437...	lld:pubmed
pubmed-article:15264437	pubmed:meshHeading	pubmed-meshheading:15264437...	lld:pubmed
pubmed-article:15264437	pubmed:year	2004	lld:pubmed
pubmed-article:15264437	pubmed:articleTitle	Technology evaluation: pertuzumab, Roche/Genentech/Chugai.	lld:pubmed
pubmed-article:15264437	pubmed:affiliation	Guy's Hospital, Department of Medical Oncology, 3rd Floor, New Guy's House, St Thomas Street, London SE1 7EH, UK. James.Spicer@gstt.nhs.uk	lld:pubmed
pubmed-article:15264437	pubmed:publicationType	Journal Article	lld:pubmed
pubmed-article:15264437	pubmed:publicationType	Review	lld:pubmed
http://linkedlifedata.com/r...	pubmed:referesTo	pubmed-article:15264437	lld:pubmed